January 23, 2014
by admin
8 Comments
With the details from the DEMAND-III study, the full extent of the failure of Prosensa’s exon-skipping drug drisapersen to arrest progression of Duchenne Muscular Dystrophy (DMD) has become clear. There are few grounds for optimism among the plethora of secondary … Continue reading
January 3, 2014
by admin
1 Comment
With thirty-nine approvals from the FDA, 2012 triggered a wave of optimism in the pharmaceutical industry. But if 2012 was characterized by an increased number of approvals, the sales potential of many of those new products was underwhelming. For 2013, … Continue reading